Edited by: Suneil Jain and Helen McCarthy
Prostate cancer is the most commonly diagnosed cancer in men. Localized disease is commonly treated with androgen deprivation therapy, surgery or radiotherapy but currently many men develop metastatic castrate resistant prostate cancer.
Novel approaches for early diagnosis and improved therapy are required. This series in Cancer Nanotechnology provides a collection of original papers and expert reviews covering a broad range of nanomedical approaches to improving outcomes in prostate cancer.
Nanoparticles have enormous potential to act as radiosensitizers, and targeted therapies are being refined for clinical use with the potential to enhance image guided radiotherapy. Furthermore, many nanoparticles have been designed as drug delivery agents with the promise of delivering increased therapeutic payloads directly to the tumor.
New articles in the series will be added here as they are published.